Loading…
No business profile yet.
Size PureTech Health (PRTC.L) is a United Kingdom Health Care company (Biotechnology) with a market value of $394M, the 327th largest of 363 United Kingdom companies the cockpit tracks. Shares closed at £119.40 on 6 Nov 2026.
Performance Over six months the shares fell 7.6%, against -32.8% for the median peer and +3.6% for the United Kingdom market (cap-weighted) — 2nd highest of 21 in its peer set.
Growth Revenue fell 4.1% over the last twelve months (peer median +7.2%); the operating margin is -1,616.9% (peer median -59.9%).
Valuation It trades at 28.4× enterprise value to sales against a peer median of 5.3× (5th most expensive of 16).
Capital Return on invested capital runs 56.9 points below its cost of capital (12.0% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | £4.74M | £3.54M | £3.78M | £2.68M | £12.7M |
| Revenue growth | — | -6% | +41% | -79% | — |
| Gross profit | £2.28M | £994,772 | £983,713 | -£1.29M | n/a |
| EBITDA | -£74.2M | -£72.2M | -£104M | -£114M | -£153M |
| Net income | £1.35M | -£83.3M | £41.9M | -£52.9M | -£40.9M |
| Free cash flow | -£61.2M | -£64.6M | -£105M | -£85.3M | -£147M |
| Capital expenditure | £4,481 | £4,553 | £8,608 | £197,096 | £1.77M |
| Total debt | n/a | £14.7M | £18.0M | £20.0M | £61.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PRTC.L | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.6% | -13.4% | 2nd highest of 21 |
| 6-month return | -7.6% | -32.8% | 2nd highest of 21 |
| Distance from 52-week high | -16.9% | -51.1% | highest of 21 |
| Revenue growth (TTM) | -4.1% | +7.2% | 6th lowest of 17 |
| Operating margin | -1,616.9% | -59.9% | 4th lowest of 17 |
| EV / Sales | 28.4× | 5.3× | 5th most expensive of 16 |
| ROIC minus cost of capital | -56.9 pp | -9.0 pp | 3rd lowest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PureTech Health PRTC.L | United Kingdom | $394M | -8% | -4% | -1,617% | 28.4× | n/a | n/a |
| Zura Bio ZURA | United States | $394M | -15% | n/a | n/a | n/a | n/a | n/a |
| Editas Medicine EDIT | United States | $395M | -17% | +21% | -178% | 5.4× | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | 5.7× | 2.0% | +725.2% |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | 244.5× | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $384M | -23% | -4% | -4% | 2.7× | n/a | n/a |
| Altimmune ALT | United States | $405M | -33% | +55% | -320,726% | 3,686.9× | n/a | n/a |
| C4 Therapeutics CCCC | United States | $381M | +5% | +2% | -288% | 5.3× | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $381M | -34% | n/a | n/a | n/a | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $408M | -45% | +1,418% | 26% | 0.9× | -15.8% | +197.3% |
| Prothena PRTA | United States | $409M | -26% | +427% | -110% | 2.4× | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $410M | -19% | +3% | 0% | 1.6× | 43.0% | +8.9% |
| AgomAb Therapeutics NV ADR AGMB | United States | $376M | -37% | n/a | n/a | n/a | n/a | n/a |
| CorMedix CRMD | United States | $415M | -33% | +280% | 47% | 0.7× | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $415M | -17% | +230% | 56% | 2.5× | -20.2% | n/a |
| Kamada KMDA | United States | $417M | -15% | +11% | 14% | 1.8× | 4.1% | +6.5% |
| G2GBIO 456160.KS | South Korea | $370M | -65% | -45% | -2,884% | 775.0× | n/a | n/a |
| Arvinas ARVN | United States | $420M | -37% | -12% | -10% | n/a | n/a | n/a |
| Surrozen SRZN | United States | $364M | -35% | -9% | -385% | 23.3× | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $364M | -23% | -55% | -729,281% | 7,653.4× | n/a | n/a |